Clinical Trial Update: Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ibrutinib versus temsirolimus in relapsed/refractory mantle cell lymphoma; results completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2017-03-01